Citations

Clear

1446 citation(s) found for "Howard, F".

Blood Culture Use in Medical and Surgical Intensive Care Units and Wards
Hsu, Yea‐Jen , Salinas, Alejandra , Gadala, Avinash , Bower, Chris , Degnan, Kathleen, Dhaubhadel, Pragya, Drees, Marci , Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glaser, Laurel , Johnson, J. Kristie, Kim, Justin , Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Robinson, Evan D. , Rodriguez‐Nava, Guillermo , Salinas, Jorge , Schrank, Gregory M. , Shah, Aditya , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Cosgrove, Sara E. , Fabre, Valeria , Carroll, Karen C. , Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Howard‐Anderson, Jessica , Mathers, Amy J. , Moehring, Rebekah W. , Nelson, George E. , O’Horo, John C. , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van

Mayo Clinic

JAMA Network Open | January 15, 2025 | Volume: 8 | Issue: 1 | Pages: e2454738

10.1001/jamanetworkopen.2024.54738 | PMID 39813030 Get It

ImportanceBlood culture (BC) use benchmarks in US hospitals have not been defined.ObjectiveTo characterize BC use in adult intensive care units (ICUs) and wards in US hospitals.Design, Setting, and ParticipantsA retrospective cross-sectional study of BC use in adult medical ICUs, medical-surgical ICUs, medical wards, and medical-surgical wards from acute care hospitals from the 4 US geographic regions was conducted. Critical access hospitals, less than 6 months of BC data, and non-US hospitals were excluded. The study included BC use data from September 1, 2019, to August 31, 2021. Data were analyzed from February 23 to July 14, 2024.Main Outcomes and MeasuresThe primary outcome was BC use per 1000 patient-days. Adjusted means with 95% CIs were calculated using mixed-effects negative binomial regression models adjusted for unit type, hospital bed size, geographic region, seasonality, and state COVID-19 case load, with random intercepts accounting for clustering at unit and hospital levels. Secondary outcomes included blood culture positivity, single BCs, BC contamination, and minimum threshold for BC use where blood culture positivity would be optimized.ResultsA total of 362 327 blood cultures were analyzed from 27 medical ICUs, 35 medical-surgical ICUs, 121 medical wards, and 109 medical-surgical wards from 48 hospitals in 19 states and the District of Columbia. The adjusted mean BC use per 1000 patient-days was 273.1 (95% CI, 270.2-275.9) for medical ICUs, 146.0 (95% CI, 144.5-147.5) for medical-surgical ICUs, 80.3 (95% CI, 79.8-80.7) for medical wards, and 65.1 for medical-surgical wards. Blood culture use was significantly higher across all 4 unit types in hospitals with more than 500 beds compared with 500 or less beds and in the West-Midwest compared with other regions. Single blood culture and positive blood culture rates were below 10% across all 4 unit types. Of the 292 units, 97% had a mean BC contamination rate within 3% of the recommended threshold, and 51% were within 1%. The minimum BC use thresholds (ie, BC use below this number may represent undertesting) were 120 BCs per 1000 patient-days for medical ICUs, 80 BCs per 1000 patient-days for medical-surgical ICUs, and 30 BCs per 1000 patient-days for medical-surgical wards.Conclusions and RelevanceThe findings of this study suggest that blood culture positivity may help determine appropriate BC use for individual unit types.
Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease
Kornak, John , Staffaroni, Adam M. , Cadwallader, Claire J. , Lago, Argentina Lario , Webb, Julia D, Chen, Coty , Rascovsky, Katya, Miyagawa, Toji , Ramos, Eliana Marisa , Masdeu, Joseph C. , Pressman, Peter , Rademakers, Rosa , Kremers, Walter K. , Darby, Ryan, Pascual, Belén , Ghoshal, Nupur , Mackenzie, Ian R. , Li, Jingyao , Hall, Jacob , Yutsis, Maya, Litvan, Irene , Henderson, Victor W. , Sivasankaran, Rajeev , Worringer, Katie, Domoto-Reilly, Kimiko, Snyder, Allison, Kramer, Joel H. , Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J. , Boxer, Adam L., Domoto‐Reilly, Kimiko , Damme, Philip Van , Casaletto, Kaitlin B , Masdeu, Joseph C , Pascual, Belen , Litvan, Irene , Sivasankaran, Rajeev , Boeve, Brad , Van Damme, Philip , Kremers, Walter K , Domoto-Reilly, Kimiko , Saloner, Rowan , Villeda, Saul , Paolillo, Emily W. , VandeBunte, Anna M. , Pantelyat, Alexander , Tartaglia, Maria Carmela , Bozoki, Andrea C , Younes, Kyan , Lapid, Maria I. , Hsiung, Ging‐Yuek Robin , Worringer, Katie, Loureiro, Joseph , Boeve, Bradley F. , Rojas, Julio C. , Boxer, Adam L.

Mayo Clinic

Brain Communications | January 15, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcae432 | PMID 39816189 Get It

Abstract The largest risk factor for dementia is age. Heterochronic blood exchange studies have uncovered age-related blood factors that demonstrate ‘pro-aging’ or ‘pro-youthful’ effects on the mouse brain. The clinical relevance and combined effects of these factors for humans is unclear. We examined five previously identified brain rejuvenation factors in cerebrospinal fluid of adults with autosomal dominant forms of frontotemporal dementia and sporadic Alzheimer’s disease. Our frontotemporal dementia cohort included 100 observationally followed adults carrying autosomal dominant frontotemporal dementia mutations (Mage = 49.6; 50% female; 43% C9orf72, 24% GRN, 33% MAPT) and 62 non-carriers (Mage = 52.6; 45% female) with cerebrospinal fluid analysed on Somascan, and longitudinal (Mvisits = 3 years, range 1–7 years) neuropsychological and functional assessments and plasma neurofilament light chain. Our Alzheimer’s disease cohort included 35 adults with sporadic Alzheimer’s disease (Mage = 69.4; 60% female) and 56 controls (Mage = 68.8, 50% female) who completed the same cerebrospinal fluid and clinical outcome measures cross-sectionally. Levels of C-C motif chemokine ligand 11, C-C motif chemokine ligand 2, beta-2-micorglobulin, bone gamma-carboxyglutamate protein (aka Osteocalcin) and colony stimulating factor 2 in cerebrospinal fluid were linearly combined into a composite score, with higher values reflecting ‘pro-youthful’ levels. In genetic frontotemporal dementia, higher baseline cerebrospinal fluid rejuvenation proteins predicted slower decline across cognitive, functional, and neurofilament light chain trajectories; estimates were similar across genotypes. In transdiagnostic analyses, higher cerebrospinal fluid rejuvenation proteins associated with better functional, cognitive, and neurofilament light chain outcomes in adults with sporadic Alzheimer’s disease. Proteins with pre-clinical evidence for brain rejuvenation show translational clinical relevance in adults with Alzheimer’s disease and related dementias and warrant further investigation.
Subjective cognitive concerns are associated with unsupervised smartphone‐based measures of memory and executive functioning in cognitively intact adults
Dhanam, Sreya , Young, Clayton, Taylor, Jack C. , Wise, Amy B. , Clark, Annie L , Heuer, Hilary W. , Kwang, Winnie, Kramer, Joel H. , Rosen, Howard J. , Weiner, Michael W. , Nosheny, Rachel L. , Staffaroni, Adam M. , Boxer, Adam L. , Bui, Minh , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.093471 Get It

AbstractBackgroundSubjective cognitive concerns are common in functionally intact adults, potentially indicating future cognitive decline. Remote smartphone cognitive testing holds promise for objectively tracking cognition in individuals reporting complaints. In our initial exploration of the link between subjective cognitive complaints and digital clinical outcomes, we examined participants' self‐reported cognitive complaints' association with smartphone tests on memory and executive functioning.MethodsParticipants, without self‐reported MCI or dementia, were recruited from the UCSF Brain Healthy Registry (BHR) to complete cognitive tasks on their personal smartphone with the ALLFTD Mobile App. Participants also completed the 12‐item Everyday Cognition Screening Tool (ECog‐12), assessing subjective cognitive impairment, online as part of BHR. Average ECog‐12 scores, including Memory and Executive Functioning subdomains, were calculated. Correlations between scores from online ECog‐12 scores and app‐based smartphone tasks were examined. Regression analyses, adjusting for age, education, and sex, were performed to evaluate the relationship between ECog‐12 and smartphone tasks (Stroop & Flanker) measuring executive function and memory.ResultsOut of 2,283 invited BHR participants, 456 (mean age: 64.6 years (SD=11.8) and education: 16.3 years (SD=2.4)) completed smartphone tasks (81.1% completion rate). Age was negatively associated with executive functioning and memory tasks (β’s=‐0.51 to ‐0.54, p’s<0.05), while higher education correlated with better performance (β’s=0.10‐0.14, p’s<0.05). Sex was not significantly associated with performance on any task (β’s=‐0.04 to 0.09, p’s>0.05). Subjective cognitive concerns were linked to tasks of executive functioning (Stroop: β=‐0.18, p=0.002) and memory (β=‐0.14, p=0.02). Endorsement of executive functioning items on ECog‐12 associated with Stroop performance (β=‐0.16, p=0.005), and memory‐specific complaints were related to memory performance (β=‐0.1, p=0.09). The relationship with flanker scores was not significant (β=‐0.08, p=0.17). Similar patterns emerged with the online ECog‐12; online and app‐based scores are strongly correlated (β=0.75, p<0.05).ConclusionsIn this cognitively intact sample, subjective cognitive concerns were linked to poorer performance on ALLFTD Mobile App tasks assessing executive functioning and memory. These findings suggest that unsupervised remote smartphone testing merits further consideration to monitor cognition in individuals with subjective cognitive concerns. Subsequent studies in deeply phenotyped cohorts with follow‐up assessments are essential for understanding the clinical relevance of these results.
Clinical performance of plasma P‐tau217 for the identification of primary Alzheimer’s disease pathology or co‐pathology in sporadic frontotemporal dementia
Ljubenkov, Peter A. , Heuer, Hilary W. , Seeley, William W., Staffaroni, Adam M. , Rajbanshi, Binita, Lago, Argentina Lario , Thijssen, Elisabeth H. , Toller, Gianina , Proctor, Nicholas K. , Forsberg, Leah K. , Brushaber, Danielle , Ramos, Eliana Marisa , Coppola, Giovanni , Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan , Grant, Ian , Huey, Edward D. , Kornak, John , Lucente, Diane , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Weıntraub, Sandra , Wong, Bonnie , Rosen, Howard J. , Boxer, Adam L. , Araujo, Igor Prufer Q C, Rojas, Julio C. , VandeVrede, Lawren , Miller, Bruce L. , Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Galasko, Douglas , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Knopman, David S. , Kantarci, Kejal , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wong, Bonnie , Wszołek, Zbigniew K. , Dage, Jeffrey L. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089822 Get It

AbstractBackgroundAs new anti‐amyloid immunotherapies emerge for Alzheimer’s disease (AD), it is clear that early diagnosis of AD pathology is crucial for treatment success. This can be challenging in atypical presentations of AD and, together with our reliance on CSF or PET scans, can, at times, lead to delayed diagnosis. Here, we further explore the possible role of plasma tau phosphorylated at threonine 217 (P‐tau217) for the detection of primary AD or AD co‐pathology when frontotemporal dementia spectrum disorders are the main clinical presentation.MethodParticipants were recruited through ALLFTD, a North American multisite research consortium for the longitudinal assessment of frontotemporal lobar degeneration. After excluding cases with known FTD‐causing mutations, 573 participants with sporadic disease, mild cognitive/behavioral impairment, or healthy familial controls evaluated between 2014 and 2023 were included in this analysis (45.8% female, median age 66 years). 39 of those cases underwent neuropathological evaluation. Plasma P‐tau217 was measured with the Eli Lilly electrochemiluminescence‐based assay. P‐tau217 concentrations were compared by phenotype, disease severity, genotype, and, when available, neuropathological diagnosis with non‐parametric tests. Its diagnostic performance was tested with ROC curves. Associations between plasma P‐tau217 concentrations and clinical scales of global cognition, memory, executive function, motor function, and social cognition with linear regressions and non‐parametric tests.ResultPlasma P‐tau217 concentrations were higher in logopenic variant primary progressive aphasia (lvPPA) and amnestic dementia (AmDem), compared to participants with normal cognition or other FTD phenotypes. P‐tau217 concentrations were higher in APOE e4 carriers, compared to non‐carriers, regardless of phenotype, but were not affected by disease severity. P‐tau217 concentrations showed associations with clinical measures of global cognition, memory, and executive function, but had no associations with measures of motor function or social cognition. Plasma P‐tau217 concentrations were elevated in high and intermediate ADNC scoring, or more advanced Braak stages, even when AD was not the primary pathology.ConclusionEven when FTD is suspected, high plasma p‐tau 217 concentrations are strongly associated with underlying AD as primary pathology or contributing co‐pathology. Plasma P‐tau217 could be a tool to support the development of disease‐modifying therapies for atypical Alzheimer’s disease presentations or for FTD cases with Alzheimer’s disease co‐pathology.
GDF15 as a Prognostic Biomarker of Cognitive Decline in Frontotemporal Dementia
Chen, Coty , Cadwallader, Claire J. , Lee, Shannon Y. , Lago, Argentina Lario , Petrucelli, Leonard , Webb, Julia D, Staffaroni, Adam M. , Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J., Kramer, Joel H. , Boxer, Adam L., Casaletto, Kaitlin B. , Investigators, ALLFTD, Paolillo, Emily W. , Saloner, Rowan , VandeBunte, Anna M. , Gendron, Tania F. , Boeve, Bradley F. , Rojas, Julio C. , Boxer, Adam L. , Investigators, ALLFTD

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089335 Get It

AbstractBackgroundGrowth Differentiation Factor 15 (GDF15) is a TGF‐beta superfamily protein upregulated during immune‐mediated stress responses. Peripheral GDF15 is linked to adverse aging across organ systems including the brain. Immune dysregulation is implicated in frontotemporal dementia (FTD) pathogenesis. We examined how plasma GDF15 levels associated with longitudinal cognitive and neurofilament light chain (NfL) trajectories in adults with FTD and controls. Furthermore, we tested the utility of GDF15 as a prognostic biomarker against common inflammatory proteins (CRP and IL6).Method231 adults with FTD (24.35% sporadic FTD syndromes; 19.19% MAPT; 19.56% GRN; 22.14% C9orf72 pathogenic carriers) and 40 normal controls from the ALLFTD Consortium completed longitudinal neuropsychological testing and a blood draw with plasma analyzed on SomaScan V4.0 (baseline only: GDF15, CRP, and IL6) and Simoa (longitudinal: NfL). CRP and IL6 were selected as control markers to test the specificity of GDF15. Linear mixed effects models separately examined longitudinal cognition (global, executive functioning, memory, and language z‐scores) and plasma NfL levels as a function of baseline plasma GDF15, time, and their interaction, controlling for baseline age, sex, and education. Parallel models were conducted for CRP and IL6.ResultIn the whole cohort, higher baseline plasma GDF15 levels associated with steeper global cognitive decline (b = ‐3.91, p = 0.0092) and NfL accumulation (b = 3.88, p = 0.00088) over time. When examining cognitive domains, we found GDF15 only associated with worse executive functioning trajectories (b = ‐3.19, p = 0.0021). In contrast, baseline levels of CRP and IL6 did not display statistically significant relationships with cognitive or NfL trajectories. Prognostic effects of GDF15 remained statistically significant when restricting analyses to those with FTD pathogenic variants (b = ‐2.98, p = 0.0054 [global cognition], b = 2.69, p = 0.0098 [NfL]).ConclusionAdults with FTD and higher baseline peripheral GDF15 levels exhibit accelerated cognitive decline and neurodegeneration. Our results support GDF15 as a potential prognosticator of adverse clinical outcomes in FTD and highlight the relevance of GDF15‐specific pathways in FTD progression. Plasma GDF15 may provide utility over commonly examined inflammatory proteins and further work to explore its clinical value is indicated.
Influence of biological sex on early cognitive performance in FTLD mutation carriers: an ALLFTD study
Memel, Molly B, Alcolea, Daniel, Barroeta, Isabel , Sánchez‐Saudinós, Ma Belén, Sala, Isabel , Heuer, Hilary W. , Staffaroni, Adam M. , Casaletto, Kaitlin B. , Boxer, Adam L. , Rosen, Howard J. , Castro, J. García , Rubio‐Guerra, Sara , Selma‐González, Judit , Dols‐Icardo, Oriol , Bejanin, Alexandre , Belbin, Olivia , Fortea, Juan , Alcolea, Daniel , Carmona‐Iragui, María , Santos‐Santos, Miguel , Boeve, Bradley F. , Lleó, Alberto , Illán‐Gala, Ignacio

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.088312 Get It

AbstractBackgroundAccumulating evidence indicates that biological sex may influence clinical manifestation within the spectrum of frontotemporal lobar degeneration (FTLD), implying differences in cognitive reserve. Nonetheless, investigations into the impact of biological sex during the preclinical and minimally symptomatic stages of FTLD are lacking.MethodWe included 275 mutation carriers (158 females; 127 with C9orf72, 68 with GRN, and 80 with MAPT mutations) and 161 non‐carrier familial controls (97 females) from the ALLFTD Consortium (Staffaroni et al., Nat Medicine 2022). Participants underwent magnetic resonance imaging (MRI; 348 baseline, 338 longitudinal) and neuropsychological evaluations (394 baseline, 507 longitudinal). Behavioral symptoms were characterized with the Revised Self‐Monitoring Scale (RSMS) and the Neuropsychiatric Inventory (NPI severity scores). MRI‐derived regional volume estimates (RVE) were computed. Cognitive measures and RVE were normalized against sex‐matched controls. Cognitive composites (language, executive function, and visuospatial function) were calculated by averaging raw scores for each domain. Clinical characteristics and RVE comparisons were made between male and female participants. We adopted the residuals approach to explore behavioral and cognitive reserve by fitting a linear regression model for executive z‐scores as the response value and age, education, and RVE as explanatory variables.ResultIn mutation carriers, sex was not a significant differentiator in age, education level, disease severity, or mutation frequency. Most mutation carriers (188, 68%) were asymptomatic or mildly symptomatic at baseline. However, female mutation carriers exhibited significantly lower visuospatial performance at baseline (Cohen's d = ‐0.34, 95% CI[‐0.58, ‐0.09], p=.001). This difference remained significant among asymptomatic GRN mutation carriers (Cohen’s d = ‐0.73, 95% CI[‐1.22, ‐0.23], p=0.003) but not in other mutations. Following the residuals approach, female mutation carriers showed higher executive performance than males for the same amount of both frontotemporal and global atrophy as quantified by RVE (Cohen's d=0.45, 95 % CI[0.22, 0.67], p<.001). The observed higher executive reserve in women was particularly pronounced in C9orf72 carriers (Cohen's d=0.77, 95% CI[0.35, 1.20], p<.001) but not significant in GRN (p=0.48) and MAPT carriers (p=0.07). No differences in behavioral reserve reached statistical significance.ConclusionFemale sex might modulate early cognitive performance and confer higher executive reserve in FTLD mutation carriers.
Clinical Performance of Plasma Aβ42/Aβ40, p‐tau217 and Neurofilament Light in Sporadic Frontotemporal Dementia Spectrum Disorders with subsequent comparison of pathology
Rajbanshi, Binita, Heuer, Hilary W. , Ljubenkov, Peter A. , Lago, Argentina Lario , Staffaroni, Adam M. , Petrucelli, Leonard , Rosen, Howard J. , Boxer, Adam L. , VandeVrede, Lawren , Araujo, Igor Prufer Q C, Gendron, Tania F. , Boeve, Bradley F. , Bateman, Randall J. , Rojas, Julio C.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.091873 Get It

AbstractBackgroundIdentification of useful fluid biomarkers is expected to advance frontotemporal dementia spectrum disorders (FTD) care and therapeutic development. The clinical utility of emerging plasma Amyloid, Tau, and Neurodegeneration (ATN) biomarkers in FTD remains unexplored. This study analyzed ATN patterns by sporadic FTD phenotype, based on amyloid beta1‐42 (Aβ1‐42), amyloid beta1‐40 (Aβ1‐40), phospho‐tau217 (p‐tau217), and neurofilament (NfL) plasma concentrations.MethodThe present study included 625 participants enrolled in ALLFTD (46% female, median age 61 ± 12 years) for whom biomarker data were available. Plasma Aβ1‐42/Aβ1‐40 measures were determined by immunoprecipitation‐mass spectrometry whereas plasma p‐tau217 and NfL concentrations were respectively determined by electrochemiluminescence‐ and fluorescence‐based immunoassays. Biomarker concentrations were compared by phenotype and disease severity with ANOVA. Their diagnostic performance was tested with Receiver Operating Characteristic (ROC) curves, and biomarker relationships with measures of clinical severity were tested through linear regressions controlling for age, sex, and APOE genotype.ResultHigher plasma p‐tau217 and p‐tau217/Aβ1‐42, levels were observed in logopenic primary progressive aphasia (lvPPA) and amnestic dementia (AmD) cohorts, compared to other FTD groups. These biomarkers were not associated with disease severity but were affected by APOE4 genotype. High plasma NfL level was observed in fully symptomatic patients compared to controls, and as a function of disease severity. Plasma Aβ1‐42/Aβ1‐40 level was not different between phenotypes and was not affected by clinical severity. P‐tau217 level, but not Aβ1‐42/Aβ1‐40 or NfL levels showed high discrimination of lvPPA and AmD from other phenotypes (AUC = 0.87 (95% CI 0.77 – 0.96, p < 0.0001, 73% sensitivity, 92% specificity). The p‐tau217/Aβ1‐42 ratio improved this discrimination (AUC = 0.9, 95% CI 0.83 – 1, p < 0.0001, 77% sensitivity, 94% specificity). Plasma Aβ1‐42/Aβ1‐40, p‐tau217, NfL, p‐tau217/Aβ1‐42, p‐tau217/NfL, and (Aβ1‐42 x p‐tau217)/NfL were associated with cognitive (MoCA, CVLT), motor (UPDRS), and social behavior (RSMS) performances at baseline.ConclusionPlasma p‐tau217/Aβ1‐42 identifies, with high specificity, two phenotypes associated with Alzheimer’s disease: lvPPA and AmD. Pending molecular neuroimaging and neuropathological confirmation, this biomarker could be of value to identify primary Alzheimer’s disease pathology or co‐pathology associated with Alzheimer’s disease when sporadic FTD is suspected.
Medial temporal lobe subregional atrophy patterns in presymptomatic and symptomatic genetic frontotemporal lobar degeneration
Yballa, Claire, Mejía‐Perez, Jhony Alejandro, Wisse, Laura E.M. , Forsberg, Leah K. , Heuer, Hilary W. , Rosen, Howard J. , Boxer, Adam L. , Kantarci, Kejal, Staffaroni, Adam M. , Gaynor, Leslie S. , Cobigo, Yann , Wuestefeld, Anika , Boeve, Bradley F. , Kantarci, Kejal , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.091038 Get It

AbstractBackgroundMedial temporal lobe (MTL) atrophy is an early feature of multiple neurodegenerative diseases. In genetic frontotemporal lobar degeneration (FTLD, i.e. individuals carrying GRN, MAPT, or C9orf72 mutations), MTL atrophy can occur 10‐15 years before symptom onset. We aimed to better characterize MTL atrophy patterns in presymptomatic and symptomatic genetic FTLD using a multi‐atlas segmentation pipeline that allows precise measurement of MTL subregions.MethodParticipants included a diagnostically mixed sample of familial FTLD mutation carriers (MAPT: N=87; C9orf72: N=117; GRN: N=65) and 142 non‐carrier family member controls from the ALLFTD study cohort (Table 1). T1‐weighted MRIs were preprocessed using a multi‐atlas automated pipeline (Automatic Segmentation of Hippocampal Subfields [ASHS]) to segment the amygdala, anterior and posterior hippocampus, and MTL cortices: entorhinal cortex (ERC), perirhinal cortex or Brodmann areas (BA) 35 and 36, and parahippocampal cortex (PHC). Following rigorous quality control and manual correction (Figure 1), we assessed bilateral volume differences in mutation carriers compared to controls, adjusted for age, sex, and total intracranial volume. Analyses were conducted separately for symptomatic (FTLD‐Clinical Dementia Rating Global Score&ge;0.5) and presymptomatic (Global Score=0) mutation carriers.ResultOut of 413 scans, 317 (76.8%) segmentations passed quality control while 94 (22.8%) needed some manual edits—this was more common in symptomatic than presymptomatic carriers (32% versus 15%, p=0.001). Three scans were excluded (<1%; 2 complete scans, 1 for selected subregions) due to insufficient landmark visibility in symptomatic GRN and MAPT carriers. In symptomatic carriers, all MTL subregions demonstrated reduced volume compared to controls, although MAPT carriers exhibited particularly marked atrophy, especially in anterior MTL subregions (Table 2; amygdala, ERC, BA35, hippocampus). Presymptomatic MAPT and C9orf72 carriers also exhibited significant atrophy of primarily anterior MTL cortices, while presymptomatic GRN carriers only exhibited significantly smaller ERC volume compared to controls.ConclusionMTL atrophy is present in genetic FTLD across mutation carriers, even at the presymptomatic stage. Anterior MTL subregions, which are also susceptible to neuropathologic accumulation in early Alzheimer’s disease and Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC), tend to be more vulnerable than posterior subregions. Unsurprisingly, MAPT carriers show the greatest MTL atrophy compared to controls across groups.
Medial temporal lobe subregional atrophy patterns in presymptomatic and symptomatic genetic frontotemporal lobar degeneration
Yballa, Claire, Mejía‐Perez, Jhony Alejandro, Wisse, Laura E.M. , Forsberg, Leah K. , Heuer, Hilary W. , Rosen, Howard J. , Boxer, Adam L. , Kantarci, Kejal, Staffaroni, Adam M. , Gaynor, Leslie S. , Cobigo, Yann , Wuestefeld, Anika , Boeve, Bradley F. , Kantarci, Kejal , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093937 Get It

AbstractBackgroundMedial temporal lobe (MTL) atrophy is an early feature of multiple neurodegenerative diseases. In genetic frontotemporal lobar degeneration (FTLD, i.e. individuals carrying GRN, MAPT, or C9orf72 mutations), MTL atrophy can occur 10‐15 years before symptom onset. We aimed to better characterize MTL atrophy patterns in presymptomatic and symptomatic genetic FTLD using a multi‐atlas segmentation pipeline that allows precise measurement of MTL subregions.MethodParticipants included a diagnostically mixed sample of familial FTLD mutation carriers (MAPT: N = 87; C9orf72: N = 117; GRN: N = 65) and 142 non‐carrier family member controls from the ALLFTD study cohort (Table 1). T1‐weighted MRIs were preprocessed using a multi‐atlas automated pipeline (Automatic Segmentation of Hippocampal Subfields [ASHS]) to segment the amygdala, anterior and posterior hippocampus, and MTL cortices: entorhinal cortex (ERC), perirhinal cortex or Brodmann areas (BA) 35 and 36, and parahippocampal cortex (PHC). Following rigorous quality control and manual correction (Figure 1), we assessed bilateral volume differences in mutation carriers compared to controls, adjusted for age, sex, and total intracranial volume. Analyses were conducted separately for symptomatic (FTLD‐Clinical Dementia Rating Global Score≥0.5) and presymptomatic (Global Score = 0) mutation carriers.ResultOut of 413 scans, 317 (76.8%) segmentations passed quality control while 94 (22.8%) needed some manual edits—this was more common in symptomatic than presymptomatic carriers (32% versus 15%, p = 0.001). Three scans were excluded (<1%; 2 complete scans, 1 for selected subregions) due to insufficient landmark visibility in symptomatic GRN and MAPT carriers. In symptomatic carriers, all MTL subregions demonstrated reduced volume compared to controls, although MAPT carriers exhibited particularly marked atrophy, especially in anterior MTL subregions (Table 2; amygdala, ERC, BA35, hippocampus). Presymptomatic MAPT and C9orf72 carriers also exhibited significant atrophy of primarily anterior MTL cortices, while presymptomatic GRN carriers only exhibited significantly smaller ERC volume compared to controls.ConclusionMTL atrophy is present in genetic FTLD across mutation carriers, even at the presymptomatic stage. Anterior MTL subregions, which are also susceptible to neuropathologic accumulation in early Alzheimer’s disease and Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC), tend to be more vulnerable than posterior subregions. Unsurprisingly, MAPT carriers show the greatest MTL atrophy compared to controls across groups.
Errors on Cognitive Testing in Asymptomatic and Prodromal Familial Frontotemporal Dementia and their Prognostic Utility
Palacios, Brandon R., Casaletto, Kaitlin B. , Taylor, Jack C. , Wise, Amy B. , Dhanam, Sreya , Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J., Boxer, Adam L., Tempini, Maria Luisa Gorno , Kramer, Joel H. , Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Bui, Minh , Boeve, Bradley F. , Boxer, Adam L. , Miller, Bruce L. , Seeley, William W.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S4 | Pages: No page available

10.1002/alz.093114 Get It

AbstractBackgroundThe earliest cognitive manifestations of asymptomatic and prodromal familial frontotemporal dementia (f‐FTD) mutation carriers are still being characterized. Patients with symptomatic FTD are known to be error prone, particularly on tasks of executive function, but little is known about the frequency or predictive utility of these errors in the earliest stages of f‐FTD. The current study compared error rates on executive functioning tasks in controls and asymptomatic and prodromal mutation carriers and investigated whether errors predict worsening clinical status as follow up.MethodThis study included 90 participants (mean age = 48.57, SD = 13.30; 51.1% female; 86.67% white) with pathogenic FTD mutations (C9orf72, n = 45; GRN, n = 30; or MAPT, n = 15) who were asymptomatic or prodromal (Clinical Dementia Rating plus FTLD; CDR®+NACC‐FTLD ≤ 0.5). Propensity score matching identified (CDR®+NACC‐FTLD = 0) who did not carry pathogenic mutation but were matched on age, education, and sex. Regressions were used to compare controls and mutation carriers on error scores (rule violations and/or repetitions) from three executive functioning tasks: design fluency, lexical fluency, and Stroop inhibition. Mutation carriers with longitudinal data within 1.5 years were binarized as stable (n = 35) or progressors (n = 13) based on whether their CDR®+NACC‐FTLD sum of boxes score was worse at follow up (mean follow up = 1.07 years). Regressions were fit to evaluate the relationship between baseline error scores and group (i.e., stable vs. progressor).ResultMutation carriers committed significantly more errors than controls on the Stroop task (β = 0.67, p = 0.03) and lexical fluency (repetitions: β = 0.27, p = 0.02). The groups did not significantly differ in errors on the remaining tasks. A greater number of Stroop errors predicted mutation carriers who progressed at follow up (β = 1.04, p<0.001). When introducing the primary outcome from each task as a covariate (e.g., correct responses), the fluency task (repetitions: β = 0.10, p = 0.03) and Stroop task (errors: β = 0.82, p<0.001) were significantly associated with progression.ConclusionErrors on executive tasks may be early cognitive features in familial FTD. Importantly, errors were uniquely predictive above and beyond total scores. Research in larger samples will enable investigations of genetic differences in error rates.